Abstract

A new DNA recombinant vaccine will be administered in two doses (5 and 10 mcg) to 60 health workers to assess safety and immunogenicity. In addition it will be given in higher dose (100 mcg) to 60 dialysis patients and will be used to treat 30 persons who did not respond to the licensed plasma - derived vaccine.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL002036-02
Application #
4691950
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code